Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
As non-phagocytic eukaryotic cells can internalize particles < 1 microm in size, small size (25 to 110 nm) lipid nanocapsules (LNC) are proposed for the intracellular drug delivery of anticancer drugs to cancer cells. LNC of different diameters were loaded with etoposide or paclitaxel and subsequently tested for drug release kinetics and their efficiency to reduce cancer cell growth in cell culture. Relative high drug loads could be achieved and sustained drug release can be provided over a period of several days (etoposide) up to a few weeks (paclitaxel). While particle size exhibited only minor influences on the release kinetics, higher initial drug load led to a distinctly lower burst release. In a cancer cell culture model, etoposide or paclitaxel LNC showed a 4-fold or 40-fold higher efficiency, respectively than the drug solution while blank LNC were found to be less toxic than the pure drug at equivalent concentrations. The uptake and intracellular accumulation of LNC was confirmed by confocal laser scanning microscopy after fluorescence labeling of the nanocarriers. This nanoparticulate system is able to achieve efficient intracellular drug concentrations and seems to be therefore a promising therapeutic approach in cancer treatment.
Lacoeuille
Franck
F
Inserm U646, University of Angers, Angers, France.
Garcion
Emmanuel
E
Benoit
Jean-Pierre
JP
Lamprecht
Alf
A
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D004337:Drug Carriers; D005047:Etoposide / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008055:Lipids / Q000008:administration & dosage*; D018613:Microscopy, Confocal; D053769:Nanocapsules; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008055:Lipids; D053769:Nanocapsules; D005047:Etoposide; D017239:Paclitaxel